Skip to main content

Table 2 Panellist demographics

From: Expert opinion on diagnosing, treating and managing patients with cerebrotendinous xanthomatosis (CTX): a modified Delphi study

Panellist demographics

Number of panellists, n (%)

Professional roles of panellists

Neurologist

6 (60.0)

Metabolic specialist

1 (10.0)

Geneticist

1 (10.0)

Paediatric metabolic specialist

1 (10.0)

Other*

1 (10.0)

Place of work of panellists

Specialist centre/department

7 (70.0)

Local hospital

2 (20.0)

Other

1 (10.0)

Country panellists practice in

Italy

3 (30.0)

Israel

2 (20.0)

Turkey

2 (20.0)

France

1 (10.0)

The Netherlands

1 (10.0)

USA

1 (10.0)

Number of patients treated in the past 10 years

 ≥ 21 patients

4 (40.0)

16–20 patients

1 (10.0)

11–15 patients

2 (20.0)

6–10 patients

1 (10.0)

 ≤ 5 patients

2 (20.0)

Panellists’ experience in treating adult and paediatric patients

Adult patients only

4 (40.0)

Adult and paediatric patients

6 (60.0)

Years of experience in treating patients with CTX

 ≥ 21 years

3 (30.0)

16–20 years

2 (20.0)

11–15 years

0 (0.0)

6–10 years

3 (30.0)

 ≤ 5 years

2 (20.0)

  1. Demographics of panellists that responded to the Round 1 questionnaire
  2. *‘Other’ response selected and free-text specified as ‘pediatrician, clinical geneticist, and clinical biochemical geneticist (metabolic specialist)’
  3. ‘Other’ response selected and free-text specified as ‘university hospital’
  4. CTX: Cerebrotendinous xanthomatosis